8-K: Protagenic Therapeutics Faces Nasdaq Delisting Threat

Protagenic Therapeutics received a Nasdaq delisting notice due to insufficient stockholders' equity and delayed financial reporting.

Summary

• Protagenic Therapeutics, Inc. (PTIX) received a notification from Nasdaq Listing Qualifications Staff on November 20, 2025, indicating non-compliance with two listing rules.
• The company failed to meet Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, as reported in its Transition Report on Form 10-QT for the period ended June 30, 2025.
• Additionally, the company is non-compliant with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Due to recently regaining compliance and being under a mandatory one-year panel monitoring period, Nasdaq Staff issued a determination to delist the company's securities.
• Protagenic Therapeutics intends to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination.
• A timely hearing request will automatically stay any suspension of the company's securities for 15 calendar days, and the company will request an extended stay pending the hearing outcome.
• The company expects to file its delayed Form 10-Q imminently.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the immediate threat of delisting from Nasdaq, stemming from both financial non-compliance (insufficient stockholders' equity) and operational non-compliance (delayed filing). While the company plans to appeal, the outcome is uncertain, posing significant risk to investors.

Negatives

• Received a delisting notice from Nasdaq.
• Failed to meet the minimum stockholders' equity requirement of $2,500,000.
• Delayed filing of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Subject to a mandatory one-year panel monitoring period, which contributed to the immediate delisting determination.
• No assurance that the Nasdaq Hearings Panel will grant an extended stay or that the company will regain compliance.

Risks

• There is no assurance that the company will successfully file the Form 10-Q.
• There is no assurance that the company will otherwise meet Nasdaq compliance standards.
• There is no assurance that Nasdaq will grant the company any relief from delisting as necessary.
• There is no assurance whether the company can agree to or ultimately meet applicable Nasdaq requirements for any such relief.
• The company's securities may ultimately be delisted from The Nasdaq Capital Market.

Future Outlook

The company expects to file its delayed Quarterly Report on Form 10-Q imminently. It plans to timely request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination and will request an extended stay of suspension pending the outcome of the hearing. The company intends to present a plan to address both deficiencies at the hearing.

Management Comments

• The company is completing final steps for the Form 10-Q and expects to file it imminently.

Industry Context

This announcement highlights the ongoing challenges faced by smaller clinical-stage biopharmaceutical companies, which often operate with limited capital and can struggle to meet stringent financial and reporting compliance standards set by major exchanges like Nasdaq. Delisting threats are a significant concern in the biotech sector, particularly for companies without substantial revenue streams or late-stage products.

Comparison to Industry Standards

• Nasdaq's minimum stockholders' equity requirement of $2.5 million is a standard benchmark for continued listing on The Nasdaq Capital Market, designed to ensure a certain level of financial stability. Many smaller biotech firms, especially those in early clinical stages, frequently operate with negative equity or minimal equity, making this a common hurdle.
• Timely filing of periodic reports (e.g., Form 10-Q) is a fundamental compliance requirement across all public companies. Delays are generally viewed negatively by investors and regulators, indicating potential operational or financial issues. Compared to industry peers, consistent delays can signal a lack of robust internal controls or financial management capacity.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the continued listing of the company's stock on Nasdaq, which could lead to decreased liquidity and share price volatility.
• The company's ability to raise capital in the future may be negatively impacted by the delisting threat and compliance issues.
• Employees may face uncertainty regarding the company's future stability and operational continuity.

Next Steps

• Timely request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination.
• Request an extended stay of suspension from Nasdaq pending the outcome of the hearing.
• File the delayed Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, imminently.
• Present a plan to address both the stockholders' equity deficiency and the timely filing requirements at the Nasdaq hearing.

Key Dates

Recommendation

The company faces an imminent delisting from Nasdaq due to severe non-compliance with both financial (insufficient stockholders' equity) and reporting (delayed 10-Q) standards. While an appeal is planned, there is no assurance of a favorable outcome or that the company can regain compliance. This situation presents a high level of risk, potential loss of liquidity, and significant uncertainty for investors, warranting a strong sell recommendation.

Keywords

Nasdaq delisting, stockholders equity, financial reporting delay, Form 10-Q, compliance issues, biopharmaceutical, PTIX